An article from
Dive Brief
//
Emerging biotech
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
533 words~2 min read
